Fine
particulate matter (PM2.5) exposure can cause
lung injury and a large number of
respiratory diseases.
Sipeimine is a steroidal
alkaloid isolated from Fritillaria roylei which has been associated with anti-inflammatory,
antitussive and
antiasthmatic properties. In this study, we explored the potential effects of
sipeimine against PM2.5-induced
lung injury in Sprague Dawley rats.
Sipeimine alleviated
lung injury caused by PM2.5 and decreased
pulmonary edema,
inflammation and the levels of
tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) in the bronchoalveolar lavage fluid. In addition,
sipeimine upregulated the
glutathione (GSH) expression and downregulated the expression of
4-hydroxynonenal (4-HNE), tissue
iron and
malondialdehyde (MDA). The downregulation of
proteins involved in ferroptosis, including
nuclear factor E2-related factor 2 (Nrf2),
glutathione peroxidase 4 (GPX4),
heme oxygenase-1 (HO-1) and solute carrier family 7 member 11 (SLC7A11) was reversed by
sipeimine. The administration of RSL3, a potent ferroptosis-triggering agent, blocked the effects of
sipeimine. Using network pharmacology, we found that the effects of
sipeimine were presumably mediated through the
phosphatidylinositol 3-kinase/
protein kinase B (PI3K/Akt) signaling pathway. A PI3K inhibitor (
LY294002) blocked the PI3K/Akt signaling pathway and reversed the effects of
sipeimine. Overall, this study suggested that the protective effect of
sipeimine against PM2.5-induced
lung injury was mainly mediated through the PI3K/Akt pathway, ultimately leading to a reduction in ferroptosis.